secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001104659-22-104899
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics adds Quimi and Walbert to board after Casdin resigns
-------------------------------------------------------------------------

- Eli Casdin resigned as Class I director effective Oct 1, 2022, not due to any disagreement with the Company.
- Board expanded to 8 seats; appointed Daphne Quimi (CFO of Amicus Therapeutics) as Class I director.
- Appointed Timothy P. Walbert (CEO of Horizon Therapeutics) as Class II director.
- Quimi joins Audit and Nominating/Governance committees; Walbert joins Compensation Committee.
- Each received a non-qualified option for 39,744 shares at $9.89, vesting over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465922104899/0001104659-22-104899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465922104899/tm2227161d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-104899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer